(4,5-dihydro-1H-imidazol-2-yl)-1-methyl-1H-indole
Showing 1 - 25 of >10,000
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Philadelphia (Palbociclib, Tazemetostat,
Not yet recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Palbociclib
- +4 more
-
Philadelphia, PennsylvaniaThomas Jefferson University Hospital
Jan 13, 2023
Thyroid Cancer, Anaplastic Thyroid Cancer, Undifferentiated Thyroid Cancer Trial in Stanford (Abemaciclib)
Active, not recruiting
- Thyroid Cancer
- +2 more
-
Stanford, CaliforniaStanford University
Nov 8, 2022
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Philadelphia (STAT
Active, not recruiting
- Acute Myeloid Leukemia
- +2 more
- STAT Inhibitor OPB-111077
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Dec 20, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Venetoclax
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023
Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome Trial in Philadelphia
Recruiting
- Myelodysplastic Syndrome
- +2 more
- Navitoclax
- +6 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Feb 2, 2023
Aging Trial in Glendale
Withdrawn
- Aging
- (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
- Control
-
Glendale, ArizonaGlencroft Senior Living: Retirement Community in Arizona
Jan 30, 2023
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma Trial in
Not yet recruiting
- Anatomic Stage III Breast Cancer AJCC v8
- +14 more
- Biopsy
- +25 more
-
Portland, OregonOHSU Knight Cancer Institute
Jul 12, 2022
Recurrent Acute Myeloid Leukemia Trial in United States (Enasidenib Mesylate, Liposome-encapsulated Daunorubicin-Cytarabine)
Suspended
- Recurrent Acute Myeloid Leukemia
- Enasidenib Mesylate
- Liposome-encapsulated Daunorubicin-Cytarabine
-
Los Angeles, California
- +3 more
Sep 27, 2022
Recurrent Acute Myeloid Leukemia Trial in Duarte (Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate)
Withdrawn
- Recurrent Acute Myeloid Leukemia
- Bosutinib Monohydrate
- +6 more
-
Duarte, CaliforniaCity of Hope Meidcal Center
Jun 7, 2022
Breast Cancer, Breast Tumor Trial in Philadelphia ([18F]ISO-1)
Active, not recruiting
- Breast Cancer
- Breast Neoplasm
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania Hospital
Jan 17, 2023
Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc Trial in Stanford (Durvalumab, Carboplatin, Pemetrexed)
Recruiting
- Non Small Cell Lung Cancer
- +2 more
- Durvalumab
- +5 more
-
Stanford, CaliforniaStanford University
Oct 27, 2022
Diabetes Type 2 With Proteinuria, Diabetes, Type 2, Diabetes Trial (drug, device, diagnostic test, behavioral)
Not yet recruiting
- Diabetes Mellitus Type 2 With Proteinuria
- +12 more
- Empagliflozin 10 MG
- +6 more
- (no location specified)
Oct 17, 2023
Malignant Supratentorial Tumor, Recurrent Glioblastoma, Recurrent Gliosarcoma Trial in Houston (Lonafarnib, Temozolomide)
Active, not recruiting
- Malignant Supratentorial Neoplasm
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 13, 2021
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Cobimetinib, Enasidenib Mesylate)
Not yet recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Cobimetinib
- Enasidenib Mesylate
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 28, 2022
Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor Trial (Biospecimen Collection, Letermovir)
Not yet recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm
- Biospecimen Collection
- Letermovir
- (no location specified)
Jan 23, 2023
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Trial in United States
Suspended
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Cytarabine
- +2 more
-
Los Angeles, California
- +5 more
Dec 10, 2022
Malignant Female Reproductive System Tumor, Malignant Solid Tumor, Recurrent Malignant Female Reproductive System Tumor Trial
Not yet recruiting
- Malignant Female Reproductive System Neoplasm
- +3 more
- Biopsy
- +7 more
- (no location specified)
Nov 9, 2023
B Acute Lymphoblastic Leukemia Trial (procedure, biological, drug, radiation)
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- Biospecimen Collection
- +19 more
- (no location specified)
Nov 8, 2023
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive Trial in Columbus (other, biological, drug)
Active, not recruiting
- BRCA1 Gene Mutation
- +9 more
- Laboratory Biomarker Analysis
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Sep 16, 2022
Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,
Recruiting
- Advanced Malignant Solid Neoplasm
- +9 more
- Everolimus
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Oct 25, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Rochester (Biospecimen Collection, Bone Marrow Aspiration,
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Biospecimen Collection
- +7 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Feb 1, 2023
Bladder Carcinoma, Refractory Bladder Carcinoma, Urinary Tract Infection Trial in Buffalo (Clindamycin, Diary, Ertapenem)
Recruiting
- Bladder Carcinoma
- +2 more
- Clindamycin
- +5 more
-
Buffalo, New YorkRoswell Park Cancer Institute
May 3, 2022
COVID-19 Trial in Campos Dos Goytacazes (AZVUDINE, AZVUDINE )
Completed
- COVID-19
- AZVUDINE
- AZVUDINE placebo
-
Campos Dos Goytacazes, RJ, BrazilSanta Casa de Misericordia de Campos
Aug 10, 2022
HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1
Recruiting
- HLA-A2 Positive Cells Present
- Refractory Melanoma
- Alpha-type-1 Polarized Dendritic Cells
- +5 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Dec 12, 2022
Asthma Trial in Canada (Vitamin D, Placebo)
Recruiting
- Asthma
- Vitamin D
- Placebo
-
Vancouver, British Columbia, Canada
- +8 more
Jan 30, 2023